Press Releases Beam Therapeutics Inc.

Equities

BEAM

US07373V1052

Real-time Estimate Cboe BZX Other stock markets 02:37:34 2024-05-14 pm EDT			5-day change	1st Jan Change
23.8 ^USD	-0.94%		+5.42%	-12.75%

May. 07	Beam Therapeutics Shares Fall After Q1 Revenue Misses Estimates	MT
May. 07	Beam Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference	May. 08	GL
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results	May. 07	GL
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)	Mar. 26	GL
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)	Mar. 26	AQ
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences	Feb. 28	GL
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences	Feb. 28	AQ
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones	Feb. 27	GL
Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	Feb. 05	GL
Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	Feb. 05	AQ
Rapport Therapeutics Appoints Terry-Ann Burrell to Board of Directors	Jan. 17	AQ
Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones	Jan. 08	GL
Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 02	GL
Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors	Dec. 14	GL
Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results	Nov. 08	GL
Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference	Nov. 08	GL
Beam Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease	23-10-31	GL
Beam Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease	23-10-31	AQ
Beam Therapeutics Presents Preclinical Data Highlighting Utility and Durability of BEAM-301 to Correct a Glycogen Storage Disease Type I Deficiency Disease-Causing Mutation at ESGCT	23-10-25	GL
Beam Therapeutics Announces Portfolio Prioritization and Strategic Restructuring Focused on Potential Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline	23-10-19	GL
Beam Therapeutics Announces Portfolio Prioritization and Strategic Restructuring Focused on Potential Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline	23-10-19	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Beam CEO Andy Bromberg: Bitcoin ETFs a financialisation away from the original essence of crypto

January 30, 2024 at 02:21 pm EST